Inaugurated in Jiangbei International Branch of Nanjing Drum Tower Hospital on the morning of January 24, Jiangsu Provincial Cancer New Technology Medical Center was established with a view to further integrating various technical methods on cancer diagnostics and therapeutics, expanding the development of cancer translational medicine and application of new technologies, and putting in place a cutting-edge technologies mix portfolio and comprehensive diagnostics and therapeutics plans with Chinese characteristics. It was expected to grow into a domestically leading and provincially first-class cancer medical innovation center with distinct features and brand awareness.

Since it was approved, China (Jiangsu) Pilot FTZ Nanjing Area has been actively engaged in stepping up the development of life and health industry with energy concentrated on three aspects: first, it harnessed advantages in talent, data and clinical resources and intensified efforts on “industry-university-research-hospital” coordinated innovation in a bid to bring original new medicines and high-end medical apparatuses out of laboratories and put them into clinical use; second, it fastened pace in building a genetic public service platform, a new medicine testing public service platform, a biomedicine CDMO service platform, a one-stop service system for medicine R&D, pilot trials, testing and clinical transformation application, as well as an industrial chain integrating upstream and downstream elements; thirdly, it fast-tracked moves to deliver a medical care center in the Yangtze River Delta Region, phase-I project of the global famous doctors center, the international ophthalmology hospital and international precision medical care center, and kick-started construction of Harvard University BIDMC Hospital and Jiangbei New Compound of Jiangsu Cancer Hospital, continuously injecting fresh impetus into the development of a Gene Town.